Complete Filing Data
MindMaze Therapeutics Holding SA reported Deferred Tax Liabilities of $7.37 million for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean MindMaze Therapeutics Holding SA did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Revenue From Contracts With Customers | $6.0M | $6.1M | $3.3M |
| Research And Development Expense | $1.3M | $12.4M | $19.0M |
| Profit Loss From Operating Activities | -$110.8M | -$52.0M | -$34.3M |
| Profit Loss Before Tax | -$111.7M | -$54.3M | -$35.5M |
| Profit Loss | -$98.2M | -$50.8M | -$34.7M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax | -$484.0K | $942.0K | $152.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax | $63.0K | $461.0K | $255.0K |
| Other Comprehensive Income Net Of Tax Gains Losses On Remeasurements Of Defined Benefit Plans | -$484.0K | $942.0K | $152.0K |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | $63.0K | $461.0K | $255.0K |
| Other Comprehensive Income | -$421.0K | $1.4M | $407.0K |
| Income Tax Expense Continuing Operations | -$13.5M | -$3.5M | -$820.0K |
| Comprehensive Income | -$98.6M | -$49.4M | -$34.3M |
| Adjustments For Income Tax Expense | -$13.5M | -$3.5M | -$820.0K |
| Adjustments For Impairment Loss Recognised In Profit Or Loss Receivables | $36.0K | $24.0K | $470.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Deferred Tax Liabilities | $7.4M | $20.7M | $25.5M | $4.3M |
| Deferred Tax Assets | $589.0K | $495.0K | $1.7M | $0.00 |
| Cash And Cash Equivalents | $14.6M | $19.2M | $44.8M | $43.2M |
| Trade And Other Current Receivables | $1.2M | $1.3M | $1.3M | |
| Trade And Other Current Payables | $1.0M | $1.6M | $1.7M | |
| Rightofuse Assets | $2.6M | $2.6M | $2.5M | |
| Purchase Of Other Longterm Assets Classified As Investing Activities | $5.0K | $38.0K | $23.0K | |
| Property Plant And Equipment | $397.0K | $49.0K | $38.0K | |
| Other Noncurrent Assets | $116.0K | $114.0K | $76.0K | |
| Other Current Payables And Liabilities | $3.4M | $3.9M | $4.3M | |
| Other Current Assets | $2.0M | $1.8M | $8.5M | |
| Noncurrent Recognised Liabilities Defined Benefit Plan | $1.6M | $1.8M | $2.8M | |
| Noncurrent Liabilities | $17.3M | $32.7M | $50.4M | |
| Noncurrent Lease Liabilities | $2.1M | $2.2M | $2.2M | |
| Noncurrent Assets | $58.1M | $166.2M | $196.6M | |
| Intangible Assets Other Than Goodwill | $54.4M | $162.9M | $192.3M | |
| Financial Liabilities Due To Related Parties | $1.4M | $1.3M | $1.3M | |
| Equity And Liabilities | $76.4M | $188.8M | $251.6M | |
| Current Liabilities | $6.9M | $10.7M | $19.7M | |
| Current Lease Liabilities | $524.0K | $444.0K | $331.0K | |
| Current Assets | $18.3M | $22.6M | $55.0M | |
| Cash Flows From Used In Operating Activities | -$17.6M | -$24.1M | -$35.7M | |
| Cash Flows From Used In Investing Activities | $8.7M | -$8.0M | -$30.3M | |
| Cash Flows From Used In Financing Activities | $4.1M | $6.4M | $67.7M | |
| Assets | $76.4M | $188.8M | $251.6M | |
| Adjustments For Increase Decrease In Trade Account Payable | -$599.0K | -$75.0K | -$823.0K | |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | -$667.0K | -$79.0K | $1.3M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Proceeds From Issuing Shares | 5.0M | 60.0K | 76.1M |
| Payments Of Lease Liabilities Classified As Financing Activities | $530.0K | $390.0K | $185.0K |
| Payments For Share Issue Costs | $494.0K | $223.0K | $2.8M |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$4.9M | -$25.7M | $1.7M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $186.0K | $184.0K | -$102.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Diluted Earnings Loss Per Share | $-8.35 | $-4.81 | $-0.01 |
| Basic Earnings Loss Per Share | $-8.35 | $-4.81 | $-0.01 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Treasury Shares | 6.0M | 12.1M | 3.0M |
| Shortterm Borrowings | $337.0K | $372.0K | $95.0K |
| Share Issue Related Cost | $494.0K | $223.0K | $2.8M |
| Repayments Of Borrowings Classified As Financing Activities | $20.0K | $81.0K | $5.4M |
| Raw Materials And Consumables Used | $1.7M | $1.3M | $750.0K |
| Other Reserves | $220.3M | $221.0M | $210.1M |
| Other Losses | $48.0K | $63.0K | $752.0K |
| Other Gains | $295.0K | $1.0M | $1.2M |
| Noncurrent Provisions | $6.2M | $7.9M | $19.5M |
| Longterm Borrowings | $9.0K | $16.0K | $396.0K |
| Issued Capital | $56.2M | $56.2M | $44.1M |
| Issuance Of Treasury Shares Under Direct Share Placement Program | 102.0K | 7.1M | 50.9M |
| Inventories | $557.0K | $227.0K | $391.0K |
| Interest Received Classified As Investing Activities | $93.0K | $18.0K | $7.0K |
| Interest Paid Classified As Operating Activities | $143.0K | $374.0K | $260.0K |
| Increase Decrease Through Sharebased Payment Transactions | $814.0K | $2.2M | $1.1M |
| Increase Decrease Through Exercise Of Options | $19.0K | $60.0K | $201.0K |
| Finance Income | $93.0K | $18.0K | $97.0K |
| Finance Costs | $949.0K | $2.3M | $1.3M |
| External Selling And Distribution Expenses | $2.2M | $3.3M | $365.0K |
| Employee Benefits Expense | $11.8M | $13.0M | $9.1M |
| Earnings Before Interest Taxes Depreciation And Amortization | -$16.2M | -$30.6M | -$32.3M |
| Depreciation And Amortisation Expense | $3.3M | $3.9M | $2.0M |
| Current Provisions | $235.0K | $3.1M | $12.1M |
| Administrative Expense | $5.4M | $7.7M | $6.8M |
| Adjustments For Sharebased Payments | $814.0K | $2.2M | $1.1M |
| Adjustments For Provisions | $440.0K | -$586.0K | $100.0K |
| Adjustments For Finance Income | $93.0K | $18.0K | $97.0K |
| Adjustments For Finance Costs | $883.0K | $1.9M | $1.3M |
| Adjustments For Depreciation And Amortisation Expense | $3.3M | $3.9M | $2.0M |
Most recent annual filing with the SEC: April 30, 2024
Data sourced from SEC EDGAR public filings as of August 4, 2026.